However, despite this success in the treatment of breast cancer, the efficacy of CDK4/6 inhibition is variable, with 10–20% of tumors primarily resistant and an additional 40% becoming resistant to these drugs within the first two years109,110. This evidence concerns the gene CDK4 and breast carcinoma.